Provided herein is an antibody as well as chimeric antigen receptor (CAR) to the Aspergillus antigen p60-binding domain. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of fungal infections and cancer.

Provided are compositions and methods for detecting one or more dermatophyte organisms in a sample using capture antibodies.

Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid V.sub.HH peptide monomers, linked groups of V.sub.HH peptide monomers, V.sub.HH peptide monomers joined to antibody Fc domains, and V.sub.HH peptide monomers joined to IgG antibodies.

The present disclosure provides compositions and methods for tracking vegetation through the production and distribution cycle, and for distinguishing between plants or crops having different characteristics.

The present disclosure provides compositions and methods related to the detection of coccidioidomycosis (Valley fever). In particular, the present disclosure provides novel compositions and methods related to the detection and/or quantification of coccidioidomycosis in a subject using an enzyme-linked immunoassay (ELISA) that measures coccidioidal CTS1 antigen and/or anti-CTS1 antibodies in human serum.

The present technology is in the field of plant breeding and genetics, particularly as it pertains to the genus Cannabis. More specifically, there are provided methods and compositions for producing a population of Cannabis plants with enhanced resistance to powdery mildew. The methods use the detection of molecular genetic markers linked to powdery mildew resistance loci to select for plants displaying an enhanced powdery mildew resistance phenotype.

This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.

The present invention provides devices and methods for diagnosing and treating Coccidioides infection (valley fever). In some embodiments, the invention provides methods for identifying antigens useful in preparing similar devices for diagnosis of other pathogens of interest.

The technology provided herein relates to multiplex methods and kits for detecting different analytes and different subgroups/variations of an analyte in a sample, for example in parallel by sequential signal-encoding of said analytes, as well as in vitro methods for screening, identifying and/or testing a substance and/or drug and in vitro methods for diagnosis of a disease, and an optical multiplexing system.

Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.